TY - JOUR
T1 - Antimicrobial resistance of Neisseria gonorrhoeae in Germany
T2 - Low levels of cephalosporin resistance, but high azithromycin resistance
AU - Buder, Susanne
AU - Dudareva, Sandra
AU - Jansen, Klaus
AU - Loenenbach, Anna
AU - Nikisins, Sergejs
AU - Sailer, Andrea
AU - Guhl, Eva
AU - Kohl, Peter K.
AU - Bremer, Viviane
AU - GORENET study group
A2 - Back, Thomas
A2 - Berger, Anja
A2 - Chapot, Valerie
A2 - Steinmann, Jörg
A2 - Eicke, Stephan
A2 - Friedrichs, Claudia
A2 - Grob, Andreas
A2 - Hagedorn, Hans Jochen
A2 - Halfmann, Alexander
A2 - Hornei, Britt
A2 - Ignatius, Ralf
A2 - Korten, Simone
A2 - Sahly, Hany
A2 - Kozub-Witkowski, Elzbieta
A2 - Krämer, Sabine
A2 - Kühn, Margit
A2 - Liebetrau, Anke
A2 - Meyer, Thomas
A2 - Oberdorfer, Klaus
A2 - Pfüller, Roland
A2 - Ruckert, Caroline
A2 - Schwarz, Roman
A2 - Walch, Daniela
A2 - Mai, Madeleine
A2 - Wichelhaus, Thomas A.
A2 - Wisplinghoff, Hilmar
A2 - Wüppenhorst, Nicole
A2 - Lorenz Jäger, Jäger
A2 - Nowakowski, Elzbieta
A2 - Schlosser, Elisabeth
A2 - Sinninger, Tanja
A2 - Streit-Schmid, Doris
A2 - Mahl, Annegret
A2 - Kahle, Doris
A2 - Zimmer, Michael
A2 - Zimmer, Olga
A2 - Dreyer, Vanessa
A2 - Regnath, Thomas
A2 - Hebold, Bettina
A2 - Weber, Beatrice
A2 - Schlicht, Mirijam
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/1/17
Y1 - 2018/1/17
N2 - Background: The widespread antimicrobial resistance of Neisseria gonorrhoeae is a serious problem for the treatment and control of gonorrhoea. Many of the previously effective therapeutic agents are no longer viable. Because N. gonorrhoeae infections are not reportable in Germany, only limited data on disease epidemiology and antimicrobial susceptibility patterns are available. The Gonococcal Resistance Network (GORENET) is a surveillance project to monitor trends in the antimicrobial susceptibility of N. gonorrhoeae in Germany in order to guide treatment algorithms and target future prevention strategies. Methods: Between April 2014 and December 2015, data on patient-related information were collected from laboratories nationwide, and susceptibility testing was performed on 537 N. gonorrhoeae isolates forwarded from the network laboratories to the Conciliar Laboratory for gonococci. Susceptibility results for cefixime, ceftriaxone, azithromycin, ciprofloxacin and penicillin were defined according to EUCAST 4.0 standards. Percentages, medians and interquartile ranges (IQR) were calculated. Results: Altogether, 90% of isolates were from men. The median age was 32 (IQR 25-44) years for men and 25 (IQR 22-40) years for women (p-value < 0.001). The most frequently tested materials among men were urethral (96.1%) and rectal swabs (1.7%), and among women, it was mainly endocervical and vaginal swabs (84.3%). None of the isolates were resistant to ceftriaxone. Furthermore, 1.9% (in 2014) and 1.4% (in 2015) of the isolates were resistant to cefixime, 11.9% and 9.8% showed resistance against azithromycin, 72.0% and 58.3% were resistant to ciprofloxacin, and 29.1% and 18.8% were resistant to penicillin. Conclusions: Resistance to ceftriaxone was not detected, and the percentage of isolates with resistance to cefixime was low, whereas azithromycin resistance showed high levels during the observation period. The rates of ciprofloxacin resistance and penicillin resistance were very high across Germany. Continued surveillance of antimicrobial drug susceptibilities for N. gonorrhoeae remains highly important to ensure efficient disease management.
AB - Background: The widespread antimicrobial resistance of Neisseria gonorrhoeae is a serious problem for the treatment and control of gonorrhoea. Many of the previously effective therapeutic agents are no longer viable. Because N. gonorrhoeae infections are not reportable in Germany, only limited data on disease epidemiology and antimicrobial susceptibility patterns are available. The Gonococcal Resistance Network (GORENET) is a surveillance project to monitor trends in the antimicrobial susceptibility of N. gonorrhoeae in Germany in order to guide treatment algorithms and target future prevention strategies. Methods: Between April 2014 and December 2015, data on patient-related information were collected from laboratories nationwide, and susceptibility testing was performed on 537 N. gonorrhoeae isolates forwarded from the network laboratories to the Conciliar Laboratory for gonococci. Susceptibility results for cefixime, ceftriaxone, azithromycin, ciprofloxacin and penicillin were defined according to EUCAST 4.0 standards. Percentages, medians and interquartile ranges (IQR) were calculated. Results: Altogether, 90% of isolates were from men. The median age was 32 (IQR 25-44) years for men and 25 (IQR 22-40) years for women (p-value < 0.001). The most frequently tested materials among men were urethral (96.1%) and rectal swabs (1.7%), and among women, it was mainly endocervical and vaginal swabs (84.3%). None of the isolates were resistant to ceftriaxone. Furthermore, 1.9% (in 2014) and 1.4% (in 2015) of the isolates were resistant to cefixime, 11.9% and 9.8% showed resistance against azithromycin, 72.0% and 58.3% were resistant to ciprofloxacin, and 29.1% and 18.8% were resistant to penicillin. Conclusions: Resistance to ceftriaxone was not detected, and the percentage of isolates with resistance to cefixime was low, whereas azithromycin resistance showed high levels during the observation period. The rates of ciprofloxacin resistance and penicillin resistance were very high across Germany. Continued surveillance of antimicrobial drug susceptibilities for N. gonorrhoeae remains highly important to ensure efficient disease management.
KW - Antimicrobial resistance
KW - Gonorrhoea
KW - Neisseria gonorrhoeae
KW - Resistance surveillance
UR - http://www.scopus.com/inward/record.url?scp=85040796492&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/29343220/
U2 - 10.1186/s12879-018-2944-9
DO - 10.1186/s12879-018-2944-9
M3 - Article
C2 - 29343220
AN - SCOPUS:85040796492
SN - 1471-2334
VL - 18
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 44
ER -